Baird analyst Joel Beatty downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to Neutral with a price target of $16.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE